HTG Molecular Diagnostics (NASDAQ:HTGM) has been assigned a $3.00 target price by investment analysts at Craig Hallum in a report issued on Friday, TipRanks reports. The firm presently has a “buy” rating on the medical research company’s stock. Craig Hallum’s price objective would suggest a potential upside of 354.55% from the company’s current price.
A number of other brokerages also recently issued reports on HTGM. HC Wainwright cut their price target on shares of HTG Molecular Diagnostics from $8.00 to $4.00 and set a “buy” rating for the company in a report on Wednesday, August 7th. ValuEngine upgraded shares of HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research downgraded shares of HTG Molecular Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday, August 10th. Finally, Canaccord Genuity restated a “buy” rating and set a $3.00 price target on shares of HTG Molecular Diagnostics in a report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. HTG Molecular Diagnostics has an average rating of “Buy” and an average price target of $3.50.
HTGM traded up $0.04 during trading on Friday, reaching $0.66. The company’s stock had a trading volume of 689,500 shares, compared to its average volume of 290,544. The firm has a fifty day simple moving average of $0.90 and a two-hundred day simple moving average of $1.81. The company has a market cap of $19.29 million, a price-to-earnings ratio of -1.10 and a beta of 1.64. The company has a quick ratio of 3.34, a current ratio of 3.49 and a debt-to-equity ratio of 0.87. HTG Molecular Diagnostics has a 1 year low of $0.60 and a 1 year high of $5.30.
HTG Molecular Diagnostics (NASDAQ:HTGM) last announced its quarterly earnings results on Tuesday, August 6th. The medical research company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.02). The firm had revenue of $5.80 million for the quarter, compared to analyst estimates of $5.54 million. HTG Molecular Diagnostics had a negative return on equity of 95.77% and a negative net margin of 79.96%. As a group, equities analysts forecast that HTG Molecular Diagnostics will post -0.59 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Alambic Investment Management L.P. acquired a new stake in shares of HTG Molecular Diagnostics during the 2nd quarter worth approximately $38,000. Citadel Advisors LLC increased its holdings in HTG Molecular Diagnostics by 153.9% in the 2nd quarter. Citadel Advisors LLC now owns 38,525 shares of the medical research company’s stock valued at $64,000 after purchasing an additional 23,351 shares during the last quarter. TD Asset Management Inc. increased its holdings in HTG Molecular Diagnostics by 4.9% in the 1st quarter. TD Asset Management Inc. now owns 98,164 shares of the medical research company’s stock valued at $245,000 after purchasing an additional 4,600 shares during the last quarter. BlackRock Inc. increased its holdings in HTG Molecular Diagnostics by 504.3% in the 2nd quarter. BlackRock Inc. now owns 405,837 shares of the medical research company’s stock valued at $673,000 after purchasing an additional 338,681 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in HTG Molecular Diagnostics by 20.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,453,160 shares of the medical research company’s stock valued at $2,413,000 after purchasing an additional 242,497 shares during the last quarter. Institutional investors and hedge funds own 45.06% of the company’s stock.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing.
Recommended Story: Why does the United States have a lingering trade deficit?
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.